Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Conditions: Craniopharyngioma, Child; Craniopharyngioma; Recurrent Craniopharyngioma Interventions: Drug: Nivolumab; Drug: DAY101 Sponsors: Sabine Mueller, MD, PhD; Bristol-Myers Squibb; Day One Biopharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials